# Twilio Inc: financial statements, quarterly

TWLO · NYSE · CIK 1447669 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/twlo.md) · [Financials](/companies/twlo/financials.md) · [Filings](/companies/twlo/filings.md) · [Insiders](/companies/twlo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/twlo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,034](/filings/0001447669-24-000178.md) | [1,076 d](/filings/0001447669-26-000021.md) | [1,047](/filings/0001447669-25-000073.md) | [1,083](/filings/0001447669-25-000122.md) | [1,134](/filings/0001447669-25-000151.md) | [1,195 d](/filings/0001447669-26-000021.md) | [1,172](/filings/0001447669-26-000049.md) | [1,228](/filings/0001447669-26-000092.md) | [1,300](/filings/0001447669-25-000151.md) | [1,366 d](/filings/0001447669-26-000021.md) | [1,407](/filings/0001447669-26-000049.md) | [1,499](/filings/0001447669-26-000092.md) |
| Cost of revenue | $m | [517](/filings/0001447669-24-000178.md) | [545 d](/filings/0001447669-26-000021.md) | [503](/filings/0001447669-25-000073.md) | [527](/filings/0001447669-25-000122.md) | [555](/filings/0001447669-25-000151.md) | [595 d](/filings/0001447669-26-000021.md) | [591](/filings/0001447669-26-000049.md) | [626](/filings/0001447669-26-000092.md) | [668](/filings/0001447669-25-000151.md) | [704 d](/filings/0001447669-26-000021.md) | [723](/filings/0001447669-26-000049.md) | [773](/filings/0001447669-26-000092.md) |
| Gross profit | $m | [516](/filings/0001447669-24-000178.md) | [531 d](/filings/0001447669-26-000021.md) | [544](/filings/0001447669-25-000073.md) | [556](/filings/0001447669-25-000122.md) | [579](/filings/0001447669-25-000151.md) | [600 d](/filings/0001447669-26-000021.md) | [582](/filings/0001447669-26-000049.md) | [603](/filings/0001447669-26-000092.md) | [632](/filings/0001447669-25-000151.md) | [662 d](/filings/0001447669-26-000021.md) | [684](/filings/0001447669-26-000049.md) | [726](/filings/0001447669-26-000092.md) |
| Research and development | $m | [242](/filings/0001447669-24-000178.md) | [236 d](/filings/0001447669-26-000021.md) | [260](/filings/0001447669-25-000073.md) | [243](/filings/0001447669-25-000122.md) | [262](/filings/0001447669-25-000151.md) | [244 d](/filings/0001447669-26-000021.md) | [254](/filings/0001447669-26-000049.md) | [243](/filings/0001447669-26-000092.md) | [262](/filings/0001447669-25-000151.md) | [260 d](/filings/0001447669-26-000021.md) | [262](/filings/0001447669-26-000049.md) | [273](/filings/0001447669-26-000092.md) |
| Operating income | $m | [(109)](/filings/0001447669-24-000178.md) | [(362) d](/filings/0001447669-26-000021.md) | [(43.5)](/filings/0001447669-25-000073.md) | [(19.0)](/filings/0001447669-25-000122.md) | [(4.9)](/filings/0001447669-25-000151.md) | [13.7 d](/filings/0001447669-26-000021.md) | [23.1](/filings/0001447669-26-000049.md) | [37.0](/filings/0001447669-26-000092.md) | [40.9](/filings/0001447669-25-000151.md) | [56.8 d](/filings/0001447669-26-000021.md) | [108](/filings/0001447669-26-000049.md) | [84.5](/filings/0001447669-26-000092.md) |
| Income tax | $m | [1.7](/filings/0001447669-24-000178.md) | [5.8 d](/filings/0001447669-26-000021.md) | [10.2](/filings/0001447669-25-000073.md) | [5.6](/filings/0001447669-25-000122.md) | [6.1](/filings/0001447669-25-000151.md) | [(1.1) d](/filings/0001447669-26-000021.md) | [6.6](/filings/0001447669-26-000049.md) | [11.2](/filings/0001447669-26-000092.md) | [(4.6)](/filings/0001447669-25-000151.md) | [8.1 d](/filings/0001447669-26-000021.md) | [12.1](/filings/0001447669-26-000049.md) | [(992)](/filings/0001447669-26-000092.md) |
| Net income | $m | [(142)](/filings/0001447669-24-000178.md) | [(365) d](/filings/0001447669-26-000021.md) | [(55.3)](/filings/0001447669-25-000073.md) | [(31.9)](/filings/0001447669-25-000122.md) | [(9.7)](/filings/0001447669-25-000151.md) | [(12.5) d](/filings/0001447669-26-000021.md) | [20.0](/filings/0001447669-26-000049.md) | [22.4](/filings/0001447669-26-000092.md) | [37.2](/filings/0001447669-25-000151.md) | [(45.9) d](/filings/0001447669-26-000021.md) | [90.1](/filings/0001447669-26-000049.md) | [1,067](/filings/0001447669-26-000092.md) |
| Diluted EPS | $ per share | [(0.78)](/filings/0001447669-24-000178.md) | not reported | [(0.31)](/filings/0001447669-25-000073.md) | [(0.19)](/filings/0001447669-25-000122.md) | [(0.06)](/filings/0001447669-25-000151.md) | not reported | [0.12](/filings/0001447669-26-000049.md) | [0.14](/filings/0001447669-26-000092.md) | [0.23](/filings/0001447669-25-000151.md) | not reported | [0.57](/filings/0001447669-26-000049.md) | [6.68](/filings/0001447669-26-000092.md) |
| Basic EPS | $ per share | [(0.78)](/filings/0001447669-24-000178.md) | not reported | [(0.31)](/filings/0001447669-25-000073.md) | [(0.19)](/filings/0001447669-25-000122.md) | [(0.06)](/filings/0001447669-25-000151.md) | not reported | [0.13](/filings/0001447669-26-000049.md) | [0.15](/filings/0001447669-26-000092.md) | [0.24](/filings/0001447669-25-000151.md) | not reported | [0.59](/filings/0001447669-26-000049.md) | [6.99](/filings/0001447669-26-000092.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.7](/filings/0001447669-24-000178.md) | [0.7](/filings/0001447669-26-000021.md) | [0.7](/filings/0001447669-25-000073.md) | [0.8](/filings/0001447669-25-000122.md) | [0.6](/filings/0001447669-25-000151.md) | [0.4](/filings/0001447669-26-000021.md) | [0.5](/filings/0001447669-26-000049.md) | [1.0](/filings/0001447669-26-000092.md) | [0.7](/filings/0001447669-25-000151.md) | [0.7](/filings/0001447669-26-000092.md) | [0.5](/filings/0001447669-26-000049.md) | [0.8](/filings/0001447669-26-000092.md) |
| Current assets | $bn | [4.7](/filings/0001447669-23-000226.md) | [4.9](/filings/0001447669-25-000035.md) | [4.7](/filings/0001447669-24-000074.md) | [4.0](/filings/0001447669-24-000128.md) | [3.5](/filings/0001447669-24-000178.md) | [3.4](/filings/0001447669-26-000021.md) | [3.5](/filings/0001447669-25-000073.md) | [3.5](/filings/0001447669-25-000122.md) | [3.5](/filings/0001447669-25-000151.md) | [3.6](/filings/0001447669-26-000092.md) | [3.4](/filings/0001447669-26-000049.md) | [3.7](/filings/0001447669-26-000092.md) |
| Total assets | $bn | [11.9](/filings/0001447669-23-000226.md) | [11.6](/filings/0001447669-25-000035.md) | [11.3](/filings/0001447669-24-000074.md) | [10.5](/filings/0001447669-24-000128.md) | [10.0](/filings/0001447669-24-000178.md) | [9.9](/filings/0001447669-26-000021.md) | [9.8](/filings/0001447669-25-000073.md) | [9.8](/filings/0001447669-25-000122.md) | [9.7](/filings/0001447669-25-000151.md) | [9.8](/filings/0001447669-26-000092.md) | [9.6](/filings/0001447669-26-000049.md) | [10.8](/filings/0001447669-26-000092.md) |
| Current liabilities | $bn | [0.7](/filings/0001447669-23-000226.md) | [0.7](/filings/0001447669-25-000035.md) | [0.7](/filings/0001447669-24-000074.md) | [0.7](/filings/0001447669-24-000128.md) | [0.7](/filings/0001447669-24-000178.md) | [0.8](/filings/0001447669-26-000021.md) | [0.7](/filings/0001447669-25-000073.md) | [0.7](/filings/0001447669-25-000122.md) | [0.7](/filings/0001447669-25-000151.md) | [0.9](/filings/0001447669-26-000092.md) | [0.7](/filings/0001447669-26-000049.md) | [0.8](/filings/0001447669-26-000092.md) |
| Total liabilities | $bn | [1.9](/filings/0001447669-23-000226.md) | [1.9](/filings/0001447669-25-000035.md) | [1.8](/filings/0001447669-24-000074.md) | [1.8](/filings/0001447669-24-000128.md) | [1.8](/filings/0001447669-24-000178.md) | [1.9](/filings/0001447669-26-000021.md) | [1.8](/filings/0001447669-25-000073.md) | [1.8](/filings/0001447669-25-000122.md) | [1.8](/filings/0001447669-25-000151.md) | [1.9](/filings/0001447669-26-000092.md) | [1.8](/filings/0001447669-26-000049.md) | [1.9](/filings/0001447669-26-000092.md) |
| Long-term debt | $bn | [1.0](/filings/0001447669-23-000226.md) | [1.0](/filings/0001447669-25-000035.md) | [1.0](/filings/0001447669-24-000074.md) | [1.0](/filings/0001447669-24-000128.md) | [1.0](/filings/0001447669-24-000178.md) | [1.0](/filings/0001447669-26-000021.md) | [1.0](/filings/0001447669-25-000073.md) | [1.0](/filings/0001447669-25-000122.md) | [1.0](/filings/0001447669-25-000151.md) | [1.0](/filings/0001447669-26-000092.md) | [1.0](/filings/0001447669-26-000049.md) | [1.0](/filings/0001447669-26-000092.md) |
| Shareholders' equity | $bn | [10.0](/filings/0001447669-24-000178.md) | [9.7](/filings/0001447669-26-000021.md) | [9.4](/filings/0001447669-25-000122.md) | [8.7](/filings/0001447669-25-000151.md) | [8.2](/filings/0001447669-25-000151.md) | [8.0](/filings/0001447669-26-000092.md) | [8.0](/filings/0001447669-26-000092.md) | [8.0](/filings/0001447669-26-000092.md) | [7.9](/filings/0001447669-25-000151.md) | [7.8](/filings/0001447669-26-000092.md) | [7.8](/filings/0001447669-26-000092.md) | [9.0](/filings/0001447669-26-000092.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [206 d](/filings/0001447669-24-000178.md) | [223 d](/filings/0001447669-26-000021.md) | [190](/filings/0001447669-25-000073.md) | [213 d](/filings/0001447669-25-000122.md) | [204 d](/filings/0001447669-25-000151.md) | [108 d](/filings/0001447669-26-000021.md) | [191](/filings/0001447669-26-000049.md) | [277 d](/filings/0001447669-26-000092.md) | [264 d](/filings/0001447669-25-000151.md) | [272 d](/filings/0001447669-26-000021.md) | [153](/filings/0001447669-26-000049.md) | [372 d](/filings/0001447669-26-000092.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [63.8 d](/filings/0001447669-24-000178.md) | [120 d](/filings/0001447669-26-000021.md) | [357](/filings/0001447669-25-000073.md) | [917 d](/filings/0001447669-25-000122.md) | [641 d](/filings/0001447669-25-000151.md) | [420 d](/filings/0001447669-26-000021.md) | [126](/filings/0001447669-26-000049.md) | [197 d](/filings/0001447669-26-000092.md) | [347 d](/filings/0001447669-25-000151.md) | [198 d](/filings/0001447669-26-000021.md) | [253](/filings/0001447669-26-000049.md) | [70.0 d](/filings/0001447669-26-000092.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [184](/filings/0001447669-23-000226.md) | [186](/filings/0001447669-24-000074.md) | [183](/filings/0001447669-24-000128.md) | [182](/filings/0001447669-24-000178.md) | [181](/filings/0001447669-25-000073.md) | [170](/filings/0001447669-25-000122.md) | [159](/filings/0001447669-25-000151.md) | [162](/filings/0001447669-26-000049.md) | [160](/filings/0001447669-26-000092.md) | [159](/filings/0001447669-25-000151.md) | [158](/filings/0001447669-26-000049.md) | [160](/filings/0001447669-26-000092.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 153,575,220 at 2026-07-24, from the cover of the [10-Q filed 2026-08-07](/filings/0001447669-26-000092.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.